Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Average Recommendation of “Hold” by Brokerages

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) have been assigned an average rating of “Hold” from the nine analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $14.00.

A number of equities analysts have issued reports on BCYC shares. Jefferies Financial Group reaffirmed a “buy” rating and set a $12.00 price objective on shares of Bicycle Therapeutics in a report on Thursday, April 30th. Morgan Stanley dropped their price target on shares of Bicycle Therapeutics from $13.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 8th. Citizens Jmp cut their price target on shares of Bicycle Therapeutics from $12.00 to $8.00 and set a “market outperform” rating on the stock in a report on Wednesday, March 18th. Wall Street Zen raised shares of Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Finally, Needham & Company LLC decreased their price objective on shares of Bicycle Therapeutics from $24.00 to $15.00 and set a “buy” rating for the company in a research note on Wednesday, March 18th.

Insiders Place Their Bets

In other Bicycle Therapeutics news, CEO Kevin Lee sold 5,905 shares of the business’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $4.27, for a total value of $25,214.35. Following the transaction, the chief executive officer owned 605,408 shares of the company’s stock, valued at approximately $2,585,092.16. The trade was a 0.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 9,977 shares of company stock valued at $42,702 over the last 90 days. 22.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Clearstead Advisors LLC grew its position in Bicycle Therapeutics by 234.2% during the fourth quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock valued at $33,000 after buying an additional 3,262 shares during the period. GAMMA Investing LLC grew its position in shares of Bicycle Therapeutics by 512.9% during the 2nd quarter. GAMMA Investing LLC now owns 7,704 shares of the company’s stock valued at $33,000 after acquiring an additional 6,447 shares during the period. Royal Bank of Canada increased its stake in shares of Bicycle Therapeutics by 35.5% during the 1st quarter. Royal Bank of Canada now owns 14,470 shares of the company’s stock worth $67,000 after purchasing an additional 3,788 shares during the last quarter. Brooklyn Investment Group bought a new stake in shares of Bicycle Therapeutics in the 4th quarter worth approximately $69,000. Finally, Ausdal Financial Partners Inc. bought a new stake in shares of Bicycle Therapeutics in the 2nd quarter worth approximately $70,000. 86.15% of the stock is currently owned by institutional investors.

Bicycle Therapeutics Stock Performance

Bicycle Therapeutics stock opened at $4.35 on Tuesday. Bicycle Therapeutics has a 52-week low of $3.92 and a 52-week high of $9.18. The stock’s 50 day moving average price is $4.35 and its two-hundred day moving average price is $5.18. The stock has a market capitalization of $303.67 million, a price-to-earnings ratio of -1.38 and a beta of 1.55.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings data on Thursday, April 30th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.25). The business had revenue of $0.89 million for the quarter, compared to analyst estimates of $7.50 million. Bicycle Therapeutics had a negative return on equity of 35.74% and a negative net margin of 344.95%. On average, equities research analysts forecast that Bicycle Therapeutics will post -1.97 EPS for the current year.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.